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Accumulating evidence suggests that S100B, a Ca2+-binding
protein of the EF-hand type, functions as a regulator of
intracellular activities and as an extracellular signal. Within
cells, S100B interacts with a relatively large number of
target proteins thereby regulating their functions (Figure 1).
While most of these interactions are Ca2+ dependent, in
some instances S100B/target protein interactions are not.
S100B is also secreted by certain cell types and released
byactivated/damaged/necroticcells.Secreted/releasedS100B
can aﬀect cellular functions with varying eﬀects depending
on its local concentration.
S100B is not a ubiquitous protein, its expression being
restricted to astrocytes, Schwann cells, ependymocytes,
certain neuronal populations, adipocytes, chondrocytes,
melanocytes, dendritic cells, muscle satellite cells, skeletal
myoﬁbers, arterial smooth muscle cells, and bronchial
epithelium, in normal physiological conditions. However,
the S100B cell expression pattern during prenatal and
postnatal development might be diﬀerent (there is limited
information about this issue); S100B expression levels in
certain cell types may be varied in response to extracellular
factors; levels of S100B are high in several cancer cells;
S100B expression may be induced in cardiomyocytes and
arterial endothelium in response to norepinephrine. Serum
levels of S100B in normal prepubescent and postpubescent
human subjects are relatively high and low, respectively, and
increases in S100B serum levels are found in physiological
conditions (such as intense physical exercise) and in sev-
eral pathological conditions (mostly, brain diseases, certain
psychiatric disorders, melanoma, and heart infarction and
insuﬃciency).
The present special issue of “Cardiovascular Psychiatry
and Neurology” focuses on the brain-heart role of S100B. In
the adult brain, S100B amounts to ∼0.5% of cytoplasmic
protein content and is most abundant in astrocytes (with
an estimated concentration of ∼10µM), where the protein
is found diﬀusely in the cytoplasm and associated with
microtubules, GFAP intermediate ﬁlaments, and intracellu-
lar membranes. Such a high concentration and its diﬀuse
localization in the cytoplasm explain S100B’s ability to
interact with enzymes, enzyme substrates, scaﬀold/adaptor
proteins, transcription factors, and cytoskeleton constituents
thereby regulating energy metabolism, Ca2+ homeostasis,
transcription, and cell shape, proliferation, diﬀerentiation,
and motility (Figure 1). Besides, ∼5% of S100B is being
constitutively secreted by astrocytes; S100B secretion can
be enhanced or reduced by a number of factors and/or
conditions; in case of brain damage, large amounts of S100B
are being passively released, with a fraction of the protein
diﬀusing into the cerebrospinal ﬂuid (CSF) and blood.
Whereas increases in the CFS and/or serum S100B
content are taken as an indication of brain damage (yet
increases in serum S100B content might point to nonbrain
damage as well), a large body of evidence indicates that brain
extracellular S100B behaves as a neurotrophin in normal
physiological conditions and as a damage-associated molec-
ularpattern(DAMP)factoruponmassivereleaseconsequent
to astrocyte activation or necrosis. In this latter case, S100B2 Cardiovascular Psychiatry and Neurology
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Figure 1: Schematic representation of intracellular regulatory eﬀects of S100B.
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Figure 2: Schematic representation of extracellular regulatory eﬀects of S100B on neurons, microglia, and astrocytes.
participates in the ampliﬁcation of the brain inﬂammatory
response by activating microglia and astrocytes and exerting
toxic eﬀects on neurons. RAGE (receptor for advanced
glycation end products) has been identiﬁed as the receptor
transducing both trophic and toxic eﬀects of S100B in the
brainandmightactasacoreceptorsupportingcertainS100B
eﬀects on microglia (Figure 2).
As an intracellular regulator, S100B also participates
in myocardium remodeling post infarction inhibiting the
hypertrophic response in cardiomyocytes surviving the
insult, and once released from necrotic cardiomyocytes, it
acts as a DAMP factor causing cell death again via RAGE
engagement. Adipocytes also release S100B in response to
catecholamines with unidentiﬁed eﬀects, though. Lastly, as a
DAMPfactor,S100B alsoparticipates in the pathophysiology
of atherosclerosis stimulating vascular smooth cell prolifera-
tion and activating monocytes/macrophages.
The present issue of “Cardiovascular Psychiatry and
Neurology” attempts to delineate the functional roles of
S100B in the brain and the cardiovascular apparatus and
to update the information about this multifaceted protein.
We are conﬁdent that both cell biologists and clinicians will
beneﬁt by the reading of the papers presented therein.
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